Lagerström P O, Persson B A
J Chromatogr. 1984 Aug 10;309(2):347-56. doi: 10.1016/0378-4347(84)80042-0.
Omeprazole, a substituted benzimidazole and a new gastric acid inhibitor, has been determined in plasma and urine, together with three of its metabolites--the sulphide, the sulphone and the hydroxy compound. The methods comprise extraction from the biological materials with methylene chloride, followed either by direct injection of the extract onto a normal-phase liquid chromatography column or evaporation, dissolution and injection onto a reversed-phase system. The compounds were detected using ultraviolet spectrometry. The absolute recoveries obtained were mostly above 95%. The minimum determinable concentration for omeprazole was 20 nmol/l in plasma (relative standard deviation 10-15%) and 50 nmol/l in urine. The metabolites could also be determined at the same levels.
奥美拉唑是一种取代苯并咪唑类新型胃酸抑制剂，已在血浆和尿液中与其三种代谢物——硫化物、砜和羟基化合物一同被测定。这些方法包括用二氯甲烷从生物材料中提取，然后将提取物直接注入正相液相色谱柱，或者进行蒸发、溶解后注入反相系统。使用紫外光谱法检测这些化合物。所获得的绝对回收率大多在95%以上。奥美拉唑在血浆中的最低可测定浓度为20纳摩尔/升（相对标准偏差为10 - 15%），在尿液中为50纳摩尔/升。这些代谢物也能在相同水平下被测定。
